Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,272.00    30.00 (1.34%)
Bid:
2,270.00
Ask:
2,278.00
Spread: 8.00 (0.352%)
Market Cap: £1.51b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

22 Sep 2010 14:49

RNS Number : 1319T
Genus PLC
22 September 2010
 

22 September 2010

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that conditional nil-cost share options were granted under the Genus 2004 Performance Share Plan ("the Plan") today to Richard Wood, Chief Executive, as to 57,631 ordinary shares of 10 pence each in the Company ("Ordinary Shares"). These options are subject to performance conditions which relate to growth in the Company's earnings per share over a three year period and which trigger vesting on an incremental basis.

 

Genus further announces that of 154,639 Ordinary Shares that vested today in favour of Richard Wood, Chief Executive, under the Plan, 154,639 Ordinary Shares were today sold on behalf of Richard Wood at a price of 770 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 60,856 Ordinary Shares which represents 0.102% of the issued share capital of the Company which is currently 59,678,535 Ordinary Shares. In addition, he remains the beneficial owner of 195,457 conditional nil-cost options under the Plan.

 

Genus also announces that of 34,364 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 34,364 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 770 pence per Ordinary Share. Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.006% of the issued share capital of the Company. In addition, he remains the beneficial owner of 109,530 conditional nil-cost options under the Plan.

 

Of 33,505 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 33,505 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 770 pence per Ordinary Share.

Thomas Philip Acton's direct shareholding in the Company stands at 21,104 Ordinary Shares which represents 0.035% of the issued share capital of the Company. In addition, he remains the beneficial owner of 103,084 conditional nil-cost options under the Plan.

 

Of 17,182 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 17,182 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 770 pence per Ordinary Share. Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 75,018 conditional nil-cost options under the Plan.

 

 

For further information please contact:

 

Cara Crichton

Company Secretarial Assistant

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUUSORRWAKUAR
Date   Source Headline
25th Sep 20206:14 pmRNSDirector/PDMR Shareholding
23rd Sep 20209:35 amRNSDirector/PDMR Shareholding
16th Sep 202012:16 pmRNSDirector/PDMR Shareholding
15th Sep 20205:52 pmRNSDirector/PDMR Shareholding
9th Sep 202012:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
8th Sep 20203:16 pmRNSApplication for Additional Listing
8th Sep 20207:00 amRNSPreliminary Results
1st Sep 20201:03 pmRNSTotal Voting Rights
3rd Aug 20204:15 pmRNSBlock listing Interim Review
1st Jul 202010:41 amRNSTotal Voting Rights
30th Jun 20203:45 pmRNSNOTIFICATION OF MAJOR HOLDINGS
29th Jun 20207:00 amRNSDirectorate Appointment
14th May 20206:23 pmRNSApplication for Block Listing
1st May 20203:04 pmRNSTotal Voting Rights
30th Apr 202010:24 amRNSCompliance with LR 9.2.6ER(1)
22nd Apr 20205:47 pmRNSDirector/PDMR Shareholding
21st Apr 202012:14 pmRNSNotification of Major Holdings
20th Apr 20209:28 amRNSDirector/PDMR Shareholding
8th Apr 20207:00 amRNSDirector/PDMR Shareholding
1st Apr 20205:52 pmRNSTotal Voting Rights
27th Feb 20207:00 amRNSInterim Results
26th Feb 202012:44 pmRNSNOTIFICATION OF MAJOR HOLDINGS
17th Feb 20205:27 pmRNSNotification of Major Holdings
7th Feb 20209:03 amRNSNotification of Major Holdings
3rd Feb 202010:51 amRNSBlock listing Interim Review
23rd Jan 20203:52 pmRNSNotification of Major Holdings
2nd Jan 202010:02 amRNSTotal Voting Rights
12th Dec 20192:17 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Dec 20194:45 pmRNSTotal Voting Rights
20th Nov 20197:00 amRNSAppointment of Chief Financial Officer
15th Nov 20196:18 pmRNSDirector/PDMR Shareholding
14th Nov 20191:23 pmRNSResult of AGM
14th Nov 20197:00 amRNSAGM TRADING UPDATE
1st Nov 201912:05 pmRNSTotal Voting Rights
14th Oct 20198:00 amRNSAnnual Report and Annual General Meeting
10th Oct 20193:30 pmRNSDirector/PDMR Shareholding
3rd Oct 20193:06 pmRNSNOTIFICATION OF MAJOR HOLDINGS
2nd Oct 20193:38 pmRNSNotification of Major Holdings
1st Oct 20195:23 pmRNSTotal Voting Rights
20th Sep 201912:38 pmRNSDirector/PDMR Shareholding
18th Sep 20196:09 pmRNSDirector/PDMR Shareholding
17th Sep 20191:24 pmRNSDirector/PDMR Shareholding
12th Sep 20192:59 pmRNSDirector/PDMR Shareholding
11th Sep 20198:02 amRNSCORRECTION: Outcome of IntelliGen Litigation
11th Sep 20197:00 amRNSOutcome of latest IntelliGen Litigation
10th Sep 20197:00 amRNSOUTCOME IN LATEST INTELLIGEN LITIGATION
5th Sep 20197:00 amRNSPreliminary Results
22nd Aug 20197:00 amRNSAppointment of Chief Executive Officer
1st Aug 20195:49 pmRNSBlock listing Interim Review
1st Aug 20195:46 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.